CorMedix Inc Net Income 2011-2021 | CRMD

CorMedix Inc net income from 2011 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
CorMedix Inc Annual Net Income
(Millions of US $)
2020 $-22
2019 $-44
2018 $-27
2017 $-33
2016 $-25
2015 $-18
2014 $-21
2013 $-10
2012 $-3
2011 $-7
2010 $-11
CorMedix Inc Quarterly Net Income
(Millions of US $)
2021-06-30 $-5
2021-03-31 $-7
2020-12-31 $-6
2020-09-30 $-7
2020-06-30 $-4
2020-03-31 $-6
2019-12-31 $-32
2019-09-30 $-5
2019-06-30 $-1
2019-03-31 $-5
2018-12-31 $2
2018-09-30 $-10
2018-06-30 $-9
2018-03-31 $-10
2017-12-31 $-10
2017-09-30 $-10
2017-06-30 $-5
2017-03-31 $-8
2016-12-31 $-7
2016-09-30 $-9
2016-06-30 $-5
2016-03-31 $-4
2015-12-31 $-4
2015-09-30 $-5
2015-06-30 $-4
2015-03-31 $-5
2014-12-31 $-2
2014-09-30 $-5
2014-06-30 $3
2014-03-31 $-17
2013-12-31 $-3
2013-09-30 $-3
2013-06-30 $-2
2013-03-31 $-2
2012-12-31 $-1
2012-09-30 $-1
2012-06-30 $-1
2012-03-31 $-1
2011-12-31 $0
2011-09-30 $-3
2011-06-30 $-2
2011-03-31 $-2
2010-12-31 $-2
2010-09-30 $-1
2010-06-30 $-1
2010-03-31 $-7
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.188B $0.000B
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its lead product Defencath (TM), a novel, antibacterial and antifungal solution designed to prevent costly and life-threatening bloodstream infections associated with the use of central venous catheters in patients undergoing chronic hemodialysis. Defencath has been designated by FDA as Fast Track and as a Qualified Infectious Disease Product, which provides an additional five years of marketing exclusivity, which will be added to the five years granted to a New Chemical Entity upon approval of the NDA. CorMedix also intends to develop Defencath as a catheter lock solution for use in oncology and total parenteral nutrition patients. It is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with programs in surgical sutures and meshes, and topical hydrog
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.527B 7.92
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.184B 20.63
Biohaven Pharmaceutical Holding (BHVN) United States $8.967B 0.00
Emergent Biosolutions (EBS) United States $2.590B 6.25
Arcus Biosciences (RCUS) United States $2.362B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.929B 0.00
Myovant Sciences (MYOV) United Kingdom $1.832B 0.00
Zymeworks (ZYME) Canada $1.055B 0.00
Ambrx Biopharma (AMAM) United States $0.463B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.159B 15.67